No Data
No Data
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Eli Lilly & Co (LLY) Receives a Buy From Barclays
Is the rebound fading? Goldman Sachs: Hedge funds are selling stocks at the fastest pace in more than two years.
In August, 'smart money' is selling global equities at the fastest pace since March 2022, with the most net selling in North America. Hedge funds are skeptical of the sustainability of the stock market rebound, and geopolitical concerns continue to be worrying. The 'fly' of the economic situation may soon hit the glass windshield.
Market Chatter: Eli Lilly's Alzheimer's Drug Expected to Be Rejected by UK Health Watchdog
Eli Lilly and Co's Alzheimer's drug, Donanemab, may be rejected by the United Kingdom's healthcare regulatory institutions.
After the regulatory institutions in the United Kingdom refused to approve Leqembi, the Alzheimer's disease drug owned by Baijian, for use in the National Health Service (NHS), there have been reports that Donanemab, another Alzheimer's disease drug owned by Eli Lilly and Co, will face the same fate.
There are many followers in the weight loss drug market, but Novo Nordisk (NVO.US) and Eli Lilly (LLY.US) will maintain a "two-horse race" situation.
Although other pharmaceutical companies are also preparing to launch GLP-1 class weight-loss drugs, they are unlikely to have a significant impact on the current dominant market positions of novo-nordisk a/s and eli lilly and co.
No Data
Green Dragon 2024 : That makes total sense. Especially, when Tom Lee stated that there should be a 40% growth in the small caps (Russell). Great information thank you!